Please login to the form below

Not currently logged in
Email:
Password:

Istodax

This page shows the latest Istodax news and features for those working in and with pharma, biotech and healthcare.

Novartis gets OK for panobinostat in myeloma

Novartis gets OK for panobinostat in myeloma

followed three years later by Celgene's rival CTCL therapy Istodax (romidepsin). .

Latest news

  • Celgene's cancer drug promising in small HIV study Celgene's cancer drug promising in small HIV study

    Lymphoma therapy Istodax shows potential in treating the virus. A cancer drug sold by Celgene could be used to drive HIV from hidden reservoirs within the body so the virus becomes ... Study leader Ole Schmeltz Søgaard from Aarhus University in Denmark

  • FDA gives early green light to Spectrum’s lymphoma drug FDA gives early green light to Spectrum’s lymphoma drug

    Spectrum's Folotyn anti-folate drug (pralatrexate) was cleared in 2009 for use in patients with relapsed or refractory PTCL while Celgene got the nod for its HDAC inhibitor Istodax (romidepsin) ... Spectrum claims Beleodaq has a broader mechanism than

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...